Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

December 12, 2023

https://www.globenewswire.com/news-release/2023/12/11/2794266/0/en/Sutro-Biopharma-Announces-New-Positive-Data-from-the-Compassionate-Use-of-Luveltamab-Tazevibulin-luvelta-in-Pediatric-Patients-with-Relapsed-Refractory-CBF-GLIS-Presented-at-ASH-20.html

– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in combination –

Read more at globenewswire.com

Related news for (STRO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.